MedTrace Logo

Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study

NCT04332835 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-11-27

No results posted yet for this study

Summary

Convalescent plasma (CP) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. In the latest viral epidemics, such as the Ebola outbreak in West Africa in 2014, the World Health Organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the Ebola virus disease by transfusion to empirically treat local infectious outbreaks

Conditions

  • Coronavirus
  • Coronavirus Infection

Interventions

DRUG

Plasma

Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.

DRUG

Standard Therapy

Standard therapy defined by institutional protocol.

Sponsors & Collaborators

  • Fundación Universitaria de Ciencias de la Salud

    collaborator OTHER

  • CES University

    collaborator OTHER

  • Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud

    collaborator UNKNOWN

  • Universidad del Rosario

    lead OTHER

Principal Investigators

  • Juan M Anaya Cabrera, MD, PhD · Universidad del Rosario

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-08
Primary Completion
2020-10-31
Completion
2020-11-15

Countries

  • Colombia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04332835 on ClinicalTrials.gov